TY - JOUR
T1 - Diagnosis and Treatment of Neurocysticercosis
T2 - 2017 Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH)
AU - White, A. Clinton
AU - Coyle, Christina M.
AU - Rajshekhar, Vedantam
AU - Singh, Gagandeep
AU - Hauser, W. Allen
AU - Mohanty, Aaron
AU - Garcia, Hector H.
AU - Nash, Theodore E.
N1 - Publisher Copyright:
© The Author(s) 2017. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved.
PY - 2018/4/3
Y1 - 2018/4/3
N2 - Gidelines for the clinical management of patients with neurocysticercosis (NCC) were prepared by a panel of the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). The guidelines are intended for infectious disease specialists, neurologists, neurological surgeons, internists, pediatricians, and family practitioners. These guidelines present our approaches to the diagnosis and management of patients with the different forms of neurocysticercosis,including viable parenchymal neurocysticercosis,single enhancing lesions, calcified parenchymal neurocysticercosis,ventricular neurocysticercosis, and subarachnoid neurocysticercosis. Our recommendations are based on the best evidence available. Due to the complex variations in clinical manifestations and the limitations of the literature, many of the recommendations are based on observational studies, anecdotal data, or expert opinion rather than randomized clinical trials. The approaches we describe are intended to be both applicable and feasible in the United States and Canada (for simplicity, referred to here as North America). The recommendations may not apply for settings where resource constraints may limit their applicability. The executive summary below lists the recommendations for the diagnosis and clinical management of neurocysticercosis. A detailed description of the methods, background, and evidence summaries that support each of the recommendations can be found online in the full text of the guidelines. A criterion for grading evidence is presented in Figure 1 [1]. Note that diagnosis and management of patients with neurocysticercosis can be challenging even with expert guidelines. Due to this complexity, clinicians with little experience with this disease should have a low threshold for consultation with an expert in the disease.
AB - Gidelines for the clinical management of patients with neurocysticercosis (NCC) were prepared by a panel of the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). The guidelines are intended for infectious disease specialists, neurologists, neurological surgeons, internists, pediatricians, and family practitioners. These guidelines present our approaches to the diagnosis and management of patients with the different forms of neurocysticercosis,including viable parenchymal neurocysticercosis,single enhancing lesions, calcified parenchymal neurocysticercosis,ventricular neurocysticercosis, and subarachnoid neurocysticercosis. Our recommendations are based on the best evidence available. Due to the complex variations in clinical manifestations and the limitations of the literature, many of the recommendations are based on observational studies, anecdotal data, or expert opinion rather than randomized clinical trials. The approaches we describe are intended to be both applicable and feasible in the United States and Canada (for simplicity, referred to here as North America). The recommendations may not apply for settings where resource constraints may limit their applicability. The executive summary below lists the recommendations for the diagnosis and clinical management of neurocysticercosis. A detailed description of the methods, background, and evidence summaries that support each of the recommendations can be found online in the full text of the guidelines. A criterion for grading evidence is presented in Figure 1 [1]. Note that diagnosis and management of patients with neurocysticercosis can be challenging even with expert guidelines. Due to this complexity, clinicians with little experience with this disease should have a low threshold for consultation with an expert in the disease.
KW - Taenia solium
KW - cysticercosis
KW - neurocysticersosis
KW - taeniasis
UR - http://www.scopus.com/inward/record.url?scp=85045149899&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85045149899&partnerID=8YFLogxK
U2 - 10.1093/cid/ciy157
DO - 10.1093/cid/ciy157
M3 - Review article
C2 - 29617787
AN - SCOPUS:85045149899
SN - 1058-4838
VL - 66
SP - 1159
EP - 1163
JO - Clinical Infectious Diseases
JF - Clinical Infectious Diseases
IS - 8
ER -